- Record: found
- Abstract: not found
- Article: not found
1256TiPA phase II, randomised, open label study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIB/C/D melanoma (NeoTrio Trial)
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.